Can we do for other essential medicines what we are doing for the COVID-19 vaccine?
Open Access
- 19 February 2021
- journal article
- editorial
- Published by BMJ in BMJ Global Health
- Vol. 6 (2), e005158
- https://doi.org/10.1136/bmjgh-2021-005158
Abstract
No abstract availableFunding Information
- Wellcome Trust (104349/Z/14/Z)
This publication has 8 references indexed in Scilit:
- Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countriesBMJ Global Health, 2020
- NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy ActionsCVD Prevention and Control, 2020
- Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular DiseasesCVD Prevention and Control, 2020
- The household economic burden of non-communicable diseases in 18 countriesBMJ Global Health, 2020
- Moving from formative research to co-creation of interventions: insights from a community health system project in Mozambique, Nepal and PeruBMJ Global Health, 2018
- Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016Bulletin of the World Health Organization, 2018
- Saving 100 million lives by improving global treatment of hypertension and reducing cardiovascular disease risk factorsThe Journal of Clinical Hypertension, 2018
- Strategies to improve the affordability of insulin in the USAThe Lancet Diabetes & Endocrinology, 2017